Miller TM, Cudkowicz ME, Shaw PJ, et al. Safety, PK, PD, and exploratory efficacy in single and multiple dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS. AAN 2019, emerging science 007.
Lixisenatide bij vroege Parkinson: minder progressie van motorische beperkingen
jun 2024 | Bewegingsstoornissen